CN113853390B - Cd147嵌合抗原受体和使用方法 - Google Patents

Cd147嵌合抗原受体和使用方法 Download PDF

Info

Publication number
CN113853390B
CN113853390B CN202080035700.8A CN202080035700A CN113853390B CN 113853390 B CN113853390 B CN 113853390B CN 202080035700 A CN202080035700 A CN 202080035700A CN 113853390 B CN113853390 B CN 113853390B
Authority
CN
China
Prior art keywords
cells
car
cell
nucleic acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080035700.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113853390A (zh
Inventor
D·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of CN113853390A publication Critical patent/CN113853390A/zh
Application granted granted Critical
Publication of CN113853390B publication Critical patent/CN113853390B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN202080035700.8A 2019-03-15 2020-02-28 Cd147嵌合抗原受体和使用方法 Active CN113853390B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819403P 2019-03-15 2019-03-15
US62/819,403 2019-03-15
PCT/US2020/020436 WO2020190483A1 (en) 2019-03-15 2020-02-28 Cd147 chimeric antigen receptors and methods of use

Publications (2)

Publication Number Publication Date
CN113853390A CN113853390A (zh) 2021-12-28
CN113853390B true CN113853390B (zh) 2025-04-25

Family

ID=72520374

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080035700.8A Active CN113853390B (zh) 2019-03-15 2020-02-28 Cd147嵌合抗原受体和使用方法

Country Status (6)

Country Link
US (1) US20220152106A1 (https=)
EP (1) EP3938402A4 (https=)
JP (2) JP7602803B2 (https=)
CN (1) CN113853390B (https=)
CA (1) CA3132458A1 (https=)
WO (1) WO2020190483A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021396332A1 (en) * 2020-12-11 2023-06-22 Purdue Research Foundation Human chimeric antigen receptor neutrophils, compositions, kits and methods of use
WO2022138282A1 (ja) * 2020-12-22 2022-06-30 荒木技研工業株式会社 金属管の分岐部構造製造装置及び金属管の分岐部構造の製造方法
WO2023147019A2 (en) * 2022-01-28 2023-08-03 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
WO2024220483A2 (en) * 2023-04-19 2024-10-24 Rutgers, The State University Of New Jersey Grp78 chimeric antigen receptors and combination therapies for treating cancer
WO2025105442A1 (ja) * 2023-11-15 2025-05-22 大塚製薬株式会社 キメラ抗原受容体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102316898A (zh) * 2008-09-29 2012-01-11 森托科尔奥索生物科技公司 抗cd147抗体、方法和用途
CN107709356A (zh) * 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003828A1 (en) * 1993-08-02 1995-02-09 Houston Biotechnology Incorporated Single-chain immunotoxin compositions and methods for preventing secondary cataracts
ES2869972T3 (es) * 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
WO2018165619A1 (en) * 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102316898A (zh) * 2008-09-29 2012-01-11 森托科尔奥索生物科技公司 抗cd147抗体、方法和用途
CN107709356A (zh) * 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞

Also Published As

Publication number Publication date
JP2025013530A (ja) 2025-01-24
CN113853390A (zh) 2021-12-28
JP7602803B2 (ja) 2024-12-19
WO2020190483A1 (en) 2020-09-24
EP3938402A1 (en) 2022-01-19
JP2022525318A (ja) 2022-05-12
CA3132458A1 (en) 2020-09-24
EP3938402A4 (en) 2023-03-08
US20220152106A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
CN113853390B (zh) Cd147嵌合抗原受体和使用方法
US11952408B2 (en) HPV-specific binding molecules
US10709775B2 (en) Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
KR102632082B1 (ko) 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도
CN112585276A (zh) 产生表达重组受体的细胞的方法和相关组合物
KR20220016475A (ko) 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
CN110997920A (zh) 新型细胞标签的表达
CN112585277A (zh) 表达重组受体的t细胞、相关多核苷酸和方法
CN112469829A (zh) 包含抗gpc3单链抗体的car
CN110944652A (zh) T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途
KR20220133318A (ko) 선택적 단백질 발현을 위한 조성물 및 방법
TW202444897A (zh) 嵌合抗原受體(car)、組合物及其使用方法
US20240216508A1 (en) Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
CN112955472A (zh) 抗ptk7免疫细胞癌症疗法
JP2024537991A (ja) 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
US20250145952A1 (en) T cells with improved functionality
EP4251176A1 (en) Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity
KR20240027676A (ko) Nr4a3-결핍 면역 세포 및 이의 용도
Kobayashi et al. The epithelial-mesenchymal transition induced by transcription factor LEF-1 is independent of β-catenin
RU2843842C1 (ru) Композиции и способы для лечения egfr-положительных форм рака
Saavedra Pérez Salas Generation of a Generic Nanobody-based CAR-T Cell Platform
JP2026507228A (ja) Ｐｓｍａ及びｃａ９を標的とするシステム
HK40115129A (zh) 具有共表达的shrna和逻辑门系统的免疫细胞
KR20240028362A (ko) Nr4a3-결핍 면역 세포 및 이의 용도
HK40119727A (zh) 包含基因表达阻遏因子和/或合成途径激活因子和/或诱导型有效载荷的细胞

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant